Pharmacogenomics in Europe

It is known that for most common diseases there are a number of medications from which to select therapy and usually a large individual variability in response to any given drug, ranging from no response to disease resolution. There is also the issue of under-representation of many countries in the development of medicines. Variation in DNA does help explain some of the differences in a persons response to a medication, but the cost of individual genetic testing will be prohibitive for many countries for the foreseeable future.

In 2010, the Golden Helix Foundation has initiated the Euro-PGx project and is coordinating the recruitment of cases from various European developing countries. The coordinator of the Euro-PGx project is Prof. George P. Patrinos and so far, the following countries have joined this initiative in Europe (in alphabetical order):

Related publications

  • Mitropoulos K, Johnson L, Vozikis A, Patrinos GP. 2011. Relevance of pharmacogenomics for developing countries in Europe. Drug Metabol Drug Interact,26(4):143-146.